23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief Executive Anne Wojcicki seeks to stabilize her money-losing business. As part of the restructuring,
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe cuts 40% of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program. “We are taking these difficult but necessary actions ...
23andMe Succumbs to Layoffs, Cutting 40% of Its Workforce
Me has announced layoffs at the organization. It will also discontinue its therapy programs and clinical trials to refocus the business.
23andMe announces workforce cut of 40% before the holidays
DNA site 23andMe is now announcing a big cut just before the holidays – the latest setback for the struggling South San Francisco startup.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe is ending its cancer research program and slashing over 200 jobs
Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a ...
23andMe warns of ‘substantial doubt’ over its survival without new funding
Genetics-testing company 23andMe has warned there is “substantial doubt” over its continued survival unless it raises new ...
cybernews37m
23andMe announces major layoffs amid financial struggles
The genetic testing company 23andMe has said it would slash 40% of its workforce after recording a drop in revenues.
STAT2h
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
FierceBiotech19h
23andMe shutters cancer drug research programs, lays off 40% of staff
23andMe is shutting down its therapeutics development division and plans to seek out buyers to find a new home for its ...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, ...
23andMe’s stock turns lower after company posts its latest quarterly loss
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported fiscal second-quarter earnings, a ...